Prognostic significance of the RT-PCR assay of PML-RARA transcripts in acute promyelocytic leukemia

Leukemia

Volumn 9, Issue 4, 1995, Pages 588-593

  Fukutani, H ^a   Naoe, T ^a   Ohno, R ^b   Yoshida, H ^a   Kiyoi, H ^a   Miyawaki, S ^c   Morishita, H ^d   Sano, F ^e   Kamibayashi, H ^f   Matsue, K ^g   Miyake, T ^h   Hasegawa, S ⁱ   Ueda, Y ^j   Kato, Y ^k   Kobayashi, H ^l   Shimazaki, C ^m   Kobayashi, M ⁿ   Kurane, R ^o   Sakota, H ^p   Masaki, K ^q   Wakayama, T ^r   Tohyama, K ^s   Nonaka, Y ^t   Natori, H ^u   more..

^a NAGOYA UNIVERSITY HOSPITAL   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SAISEIKAI MAEBASHI HOSPITAL   (Japan)

^d Suwa Red Cross Hospital   (Japan)

^e ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f Ota Nishinouchi Hospital   (Japan)

^g Kameda General Hospital   (Japan)

^h Asahikawa City Hospital   (Japan)

ⁱ ST MARIANNA UNIVERSITY   (Japan)

^j Kurashiki Chuo Hospital   (Japan)

^k AICHI MEDICAL UNIVERSITY   (Japan)

^l NAGANO RED CROSS HOSPITAL   (Japan)

^m KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

ⁿ HAMAMATSU MEDICAL CENTER   (Japan)

^o SAITAMA RED CROSS HOSPITAL   (Japan)

^p SUMITOMO HOSPITAL   (Japan)

^q Onomichi Clinic   (Japan)

^r SHIMANE UNIVERSITY   (Japan)

^s UNIVERSITY OF FUKUI   (Japan)

^t Tokyo Police Hospital   (Japan)

^u KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Acute promyelocytic leukemia; Minimal residual disease; RT PCR

Indexed keywords

CYTARABINE; DAUNORUBICIN; MESSENGER RNA; RETINOIC ACID; RETINOIC ACID RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; NEUTROPHIL; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0028908197     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Rowley JD, Golomb HM, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukemia. Lancet 1977; i: 549-554.
2. Borrow J, Goddard AD, Sheer D, Solomon E. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 1990; 249: 1577-1580.
3. de Thé H et al. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990; 347: 558-561.
4. de Thé H et al. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991; 66: 675-684.
5. Kakizuka A et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991; 66: 663-674.
6. Chen SJ et al. Rearrangements in the second intron of the RARA gene are present in a large majority of patients with acute promyelocytic leukemia and are used as molecular marker for retinoic acid-induced leukemic cell differentiation. Blood 1991; 78: 2696-2701.
7. Pandolfi PP et al. Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia. EMBO J 1992; 11: 1397-1407.
8. Fukutani H et al. Molecular heterogeneity of the PML gene rearrangement in acute promyelocytic leukemia: prevalence and clinical significance. Jpn J Cancer Res 1993; 84: 257-264.
9. Miller W Jr et al. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci USA 1992; 89: 2694-2698.
10. Castaigne S et al. A PML/retinoic acid receptor alpha fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia. Blood 1992; 79: 3110-3115.
11. Biondi A et al. Molecular monitoring of the myl/retinoic acid receptor-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood 1992; 80: 492-497.
12. Chen SJ et al. Occurrence of distinct PML-RAR-alpha fusion gene isoforms in patients with acute promyelocytic leukemia detected by reverse transcriptase/polymerase chain reaction. Oncogene 1992; 7: 1223-1232.
13. Borrow J et al. Diagnosis of acute promyelocytic leukaemia by RT-PCR: detection of PML-RARA and RARA-PML fusion transcripts. Br J Haematol 1992; 82: 529-540.
14. Yoshida H et al. Analysis of the joining sequences of the t(15;17) translocation in human acute promyelocytic leukemia: sequence non-specific recombination between the PML and RARa genes within identical short stretches. Genes Chromos Cancer 1995; 12: 37-44.
15. Grignani F et al. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 1993; 74: 423-431.
16. Grignani F et al. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994; 83: 10-25.
17. Rousselot P et al. The PML-RAR alpha gene product of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells. Oncogene 1994; 9: 545-551.
18. Pignon JM et al. Frequent detection of minimal residual disease by use of the polymerase chain reaction in long-term survivors after bone marrow transplantation for chronic myeloid leukemia. Leukemia 1990; 4: 83-86.
19. Delfau MH et al. Detection of minimal residual disease in chronic myeloid leukemia patients after bone marrow transplantation by polymerase chain reaction. Leukemia 1990; 4: 1-5.
20. Snyder DS et al. Persistence of bcr-abl gene expression following bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Transplantation 1991; 51: 1033-1040.
21. Nucifora G, Larson RA, Rowley JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 1993; 82: 712-715.
22. Maruyama F et al. Detection of AML1/ETO fusion transcript as a tool for diagnosing t(8;21) positive acute myelogenous leukemia. Leukemia 1994; 8: 40-45.
23. Chang KS et al. Expression of AML1-ETO fusion transcripts and detection of minimal residual disease in t(8;21)-positive acute myeloid leukemia. Oncogene 1993; 8: 983-988.
24. Ito Y et al. Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acute lymphoblastic leukemia. J Clin Oncol 1993; 11: 546-553.
25. Lo Coco F et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 1992; 340: 1437-1438.
26. Brisco MJ et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994; 343: 196-200.
27. Diverio D et al. Monitoring of treatment outcome in acute promyelocytic leukemia by RT-PCR. Leukemia 1994; 8: 1005-1107.
28. Ohno R et al. Multi-institutional study of all-trans retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare. Leukemia 1993; 7: 1722-1727.
29. Chomczynski P, Sacchi N. Single-step method of RNA isolation. Ann Biochem 1987; 162: 156-159.
30. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: a Laboratory Manual. 2nd edn. Cold Spring Harbor Laboratory Press: New York, 1989.
31. Knock S, Higuchi R. Avoiding false positive with PCR. Nature 1989; 339: 237-238.
32. Kiyoi H et al. Minimal residual disease status in pre-B acute lym-phoblastic leukemia patients after chemotherapy and bone marrow transplantation: assessment of the anti-leukemic effects of chemotherapy and BMT. Leukemia Res 1993; 17: 677-684.
33. Geng JP et al. Localization of the chromosome 15 breakpoints and expression of multiple PML-RAR alpha transcripts in acute promyelocytic leukemia: a study of 28 Chinese patients. Leukemia 1993; 7: 20-26.
34. Diverio D et al. Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission. Blood 1993; 82: 3556-3559.
35. Huang W et al. Acute promyelocytic leukemia: clinical relevance of two major PML-RAR alpha isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood 1993; 82: 1264-1269.
36. Miller WJ et al. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA. Blood 1993; 82: 1689-1694.
37. Gribben JG et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. New Engl J Med 1991; 325: 1525-1533.
38. Gribben JG et al. Detection by polymerase chain reaction of residual cells with bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449-3457.